



Jump | Free Trial Issue
Select Section

Search Quote

Go



HOME PAGE FOR THE WORLD'S BUSINESS LEADERS

MEMBERSHIP LOG

HOME BUSINESS TECHNOLOGY MARKETS ENTREPRENEURS WORK PERSONAL FINANCE LIFESTYLE LISTS OPIN

Home > News & Analysis

E-mail | Comments | E-Mail Newsletters | RSS

PR Newswire

Saegis Pharmaceuticals Completes Phase IIa Clinical Study of SGS518

12.15.05, 8.31 AM ET

Most Popular Stories

Most Expensive Homes In
The U.K. 2006
World's Greatest Palaces
Top Topless Beaches
Google May Be Close To
Developing iTunes
Competitor
Breakfast Battles

Most Popular Videos

Top Topless Beaches
Debating With Davos
McDonald's To Spin Off
Franchises
Banking On The Xbox 360
Where We Want To Live In
2006

HALF MOON BAY, Calif., Dec. 15 /PRNewswire/ -- Saegis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines that protect and enhance memory and cognition, announced the successful completion of a Phase IIa clinical study of SGS518. Results from the study were presented at The American College of Neuropsychopharmacology Annual Meeting. SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

The objective of this Phase IIa study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral doses of SGS518 compared to placebo when given to schizophrenia patients stable on antipsychotic medication. The efficacy

measure for cognitive changes during the course of treatment was the Brief Assessment of Cognition in Schizophrenia (BACS) developed by Richard Keefe, Ph.D. at Duke University Medical Center. The placebo-controlled, blinded study was conducted at the Claghorn-Lesem Clinic

Make Forbes.com My
Home Page

Bookmark This Page

Free Trial Issue

Gift Subscriptions



The HP ProLiant BL20p
with Intel® Xeon®
Processor and ProLiant
Essentials Rapid
Deployment Pack.



Deploy and redeploy
blades quickly
by simply dragging
and dropping
predefined
scripts or images.



in Houston, Texas.

A total of 20 patients aged 18 to 55 years of age with a DSM-IV diagnosis of stable schizophrenia were enrolled in the study. Patients were randomized into one of two dose-escalating cohorts of 10 subjects each (8 active:2 placebo) and remained in residence for 15 days. Patients were randomized to receive either a low dose-escalating regimen (60/180 mg), a high dose-escalating regimen (120/240 mg) or placebo. The total duration of treatment was 14 days. Cognition testing using the computerized BACS test was conducted prior to dosing, Day 6 prior to escalation and after receipt of the last dose on Day 13. The total duration of treatment was 14 days.

SGS518 demonstrated dose proportionality with steady state reached within 3 days. Multiple doses of up to 240 mg of SGS518 administered once daily were generally well tolerated and did not cause dose-limiting or significant toxicities. A dose response pattern of improvement observed in the BACS endpoint demonstrated statistical significance at the high dose and no effect in the placebo group. SGS518 appears to be safe and well tolerated with preliminary evidence suggesting improvement in cognition using the BACS in patients with schizophrenia.

"This study of a serotonin 5HT6 antagonist demonstrated safety in stable schizophrenic patients," said Rodney Pearlman, Ph.D., President and CEO of Saegis. "Additionally, the BACS as an efficacy endpoint has shown some encouraging data which will provide valuable direction for our ongoing Phase II clinical program. Currently, there are few, if any, therapies available for individuals suffering from Cognitive Impairment Associated with Schizophrenia and we are continuing our efforts to evaluate the efficacy of SGS518 in this patient population. It is hoped that a safe and effective treatment for the cognitive impairment in schizophrenia will help patients lead more normal and productive lives."

SGS518 is a selective antagonist of the 5-Hydroxytryptamine-6 (5-HT6) serotonin receptor believed to act by enhancing transmission of chemicals in the brain. Prior preclinical evaluation of SGS518 has shown it to be effective in behavioral studies of learning and memory. Saegis is developing SGS518 in cooperation with Eli Lilly and Company as a treatment for CIAS with some support from The Stanley Medical Research Institute. Schizophrenia affects an estimated two million people in the United States and a large proportion of these patients are believed to also suffer from cognitive impairment. While currently marketed drugs are often effective in treating the psychoses that characterizes schizophrenia, CIAS remains a significant unmet need, preventing controlled patients from leading normal lives.


About Saegis Pharmaceuticals

Saegis Pharmaceuticals is a pioneer in the development of medicines that protect and enhance the function of the human mind. Saegis is building a portfolio of compounds for the treatment of neurological conditions that impact memory and cognition, including Alzheimer's disease, adult attention deficit hyperactivity disorder (ADHD), mild cognitive impairment and Cognitive Impairment Associated with Schizophrenia (CIAS). Two of the company's orally-available small molecule compounds have demonstrated efficacy and safety in human clinical studies. Saegis' product pipeline is fueled by the discovery and identification of high-value leads leveraging comparative modeling technology of age-related cognitive decline, coupled with the strategic

Business Directory

Specials & Deals

- Investing
- Personal Finance
- Financial Planning
- Personal Technology
- Mortgages
- Lifestyles



ForbesAutos.com

Is Bigger Better?



With gas guzzlers now going green, the 'go heavy or go home' maxim no longer applies. See the biggest, the best and all the rest in our 2006 SUV Buyer's Guide.

- Hot List
- Mad Mods
- Recommended Models

Reviews, pricing and photos on 2006 SUVs on ForbesAutos.com

Eliminate ALL Debt Including Mortgage
 Free custom financial report! Eliminate all your debt. Not credit counseling. Not consolidation. Not bankruptcy. No increase in payments - Preserve your credit!
 Show me how to eliminate my debt!

Costa Rica Real Estate Opportunity
 Property values no longer control Pacific coast are skyrocketing. Now is the perfect time to invest in mountain and ocean view homes for sale at pre-development prices.
www.costaricarealestate.com

High Paying Executive Jobs from Theadders
 Click here to apply for senior level job openings in all industries. Get weekly jobs newsletter providing you with over 4000 new job opportunities. Login at
www.theadders.com

Mortgage Rates at Record Lows
 Refinance your Mortgage while rates are still low. Compare rates from up to 4 trusted lenders. It's easy, quick and free!
 - No Obligation
www.comparemortgages.com

Use MS Word as your Report Generator
 Create reports in PDF, RTF, HTML, TXT, XLS & more Use MS Word to design the reports and reduce development time by 50%. Easy-to-use custom secure in
www.wordwordreports.com

BEST AVAILABLE COPY

in-licensing and repositioning of promising clinical-stage compounds. Privately held, Saegis has received investment support from Versant Ventures, Technology Partners, Sofinnova Ventures (U.S.), Sofinnova Partners (Paris), Polaris Venture Partners, NeuroVentures, the Stanley Medical Research Institute and Novartis Pharma AG. For more information, visit www.saegispharma.com.

SOURCE Saegis Pharmaceuticals, Inc. -0- 12/15/2005 /CONTACT: Rodney Pearlman of Saegis Pharmaceuticals, Inc., +1-650-560-0210, ext. 225, or rpearlman@saegispharma.com; or Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners, for Saegis Pharmaceuticals, Inc. / Web site: <http://www.saegispharma.com> / CO: Saegis Pharmaceuticals, Inc. ST: California IN: BIO MTC HEA SU: TRI JP-ND -- SFTH022 -- 7428 12/15/2005 08:30 EST <http://www.prnewswire.com>

Copyright © 2004 PR Newswire. All rights reserved.

1 of 1

E-mail | Comments | E-Mail Newsletters | RSS 

News Headlines | More From Forbes.com | Special Reports

Subscriptions >

Free Trial Issue of Forbes
Subscribe To Newsletters

Forbes Gift Subscription
Subscriber Customer Service



Forbes
Membership

Join the Homepage
of the World's
Business Leaders

CEO Book Club

[more >](#)

BOOK REVIEW

Without A Dinar To Your Name



BOOK REVIEW

Homer 2.0

Amanda Ernst

Margaret Atwood reveals the other side of "The Odyssey."

Search Books

Title

[Advanced Search](#)

[New & Notable](#)



POWER E+TRADE

\$6.99 - \$9.99


STOCK AND
OPTIONS TRADES

E+TRADE SECURITIES LLC



Firstlight
EIRA

Synchronize
your supply chain
from beginning
to end.

 cingular

Special Advertising

Wine Club

[Go](#)

[SITEMAP](#) [HELP](#) [CONTACT US](#) [INVESTMENT NEWSLETTERS](#) [FORBES CONFERENCES](#) [FORBES MAGAZINES](#) [FORBES AUTOS](#)

Ad Information [Forbes.com Wireless](#) [RSS](#)  [Reprints/Permissions](#) [Subscriber Services](#)
© 2005 Forbes.com Inc.™ All Rights Reserved [Privacy Statement](#) [Terms, Conditions and Notices](#)

BEST AVAILABLE COPY